<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110770</url>
  </required_header>
  <id_info>
    <org_study_id>VRC 705</org_study_id>
    <nct_id>NCT03110770</nct_id>
  </id_info>
  <brief_title>VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents</brief_title>
  <acronym>DNA</acronym>
  <official_title>VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leidos Biomedical Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, study to evaluate the safety, immunogenicity, and efficacy
      of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. In Part A, the primary
      objective is to evaluate the safety and tolerability of the vaccine. In Part B, the primary
      objectives are to evaluate the safety and efficacy of the vaccine compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter,randomized study to evaluate safety, immunogenicity, and efficacy of a
      3-dose vaccination regimen with the Zika virus wildtype (ZIKVwt) DNA vaccine,
      VRC-ZKADNA090-00-VP or placebo (VRC-PBSPLA043-00-VP). The placebo is a sterile
      phosphate-buffered saline (PBS). The hypotheses are that the ZIKVwt DNA vaccine will be safe
      and will elicit a ZIKV-specific immune response.

      Participants will receive study product intramuscularly (IM) in the limbs as specified by the
      group assignment by PharmaJet needle-free device. In Part A, 90 participants will be
      randomized to vaccine at a 1:1:1 ratio to receive a 4 mg or 8 mg dose of vaccine split
      between 2 or 4 injections. In Part B, 2400 participants will be randomized to vaccine or
      placebo in a 1:1 ratio to receive a 4 mg dose of vaccine or 1 mL of placebo split between 2
      injections.

      Vaccine safety and tolerability will be assessed by monitoring of clinical and laboratory
      parameters throughout the study. Solicited reactogenicity symptoms will be collected for 7
      days after each product administration. The study schedule will include clinic visits with
      safety and immunogenicity blood samples collected at particular time points.

      The vaccine dose and administration plan for Part B was selected based on Part A and Phase 1
      data. Vaccine efficacy will be evaluated in Part B by comparing incidence of symptomatic ZIKV
      infections between vaccine and placebo groups. During the study, when participants exhibit
      any possible symptom of ZIKV infection, they will be evaluated by blood and urine ZIKV
      polymerase chain reaction (PCR). Stored blood and urine samples will also be assessed
      retrospectively by ZIKV PCR to identify possible asymptomatic cases. A Data and Safety
      Monitoring Board (DSMB) will oversee the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A participants (n=90) will be randomized to vaccine at a 1:1:1 ratio to receive a 4 mg or 8 mg dose of vaccine split between 2 or 4 injections. In Part B, 2400 participants will be randomized to vaccine or placebo in a 1:1 ratio to receive a 4 mg dose of vaccine or 1 mL of placebo split between 2 injections. The concentration and number of injections in Part B was determined by preliminary data from the Phase 1 trial and Part A.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part A is open-label. For Part A, the participant, investigator and outcome assessor will know what the participant received.
Part B injections will be prepared by an unblinded site pharmacist, designee, or otherwise qualified personnel who will not be involved in any participants assessments and who will not discuss randomizations with study clinicians. Subjects, study personnel, site data entry personnel, and laboratory personnel performing immunologic assays will be blinded to the treatment assignment of all product administrations. The IND Sponsor intends to unblind treatment assignments for Part B of the study once 90 cases of ZIKV infection are detected. The DSMB will be consulted prior to unblinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local Reactogenicity (Part A and B)</measure>
    <time_frame>7 days after each product administration</time_frame>
    <description>Occurrence of local reactogenicity signs and symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Reactogenicity (Part A and B)</measure>
    <time_frame>7 days after each product administration</time_frame>
    <description>Occurrence of systemic reactogenicity signs and symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measures (Part A)</measure>
    <time_frame>Day 0 through Day 112</time_frame>
    <description>Occurrence of laboratory safety measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measures (Part B)</measure>
    <time_frame>Day 0 through Day 308</time_frame>
    <description>Occurrence of laboratory safety measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (Part A)</measure>
    <time_frame>Day 0 through Day 224</time_frame>
    <description>Occurrence of serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (Part B)</measure>
    <time_frame>Day 0 through Day 672</time_frame>
    <description>Occurrence of serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New chronic medical conditions (Part A)</measure>
    <time_frame>Day 0 through Day 224</time_frame>
    <description>Occurrence of new-onset of chronic medical conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New chronic medical conditions (Part B)</measure>
    <time_frame>Day 0 through Day 672</time_frame>
    <description>Occurrence of new-onset of chronic medical conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed cases of Dengue virus infection (Part A)</measure>
    <time_frame>Day 0 through Day 224</time_frame>
    <description>Occurrence of confirmed cases of Dengue virus infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed cases of Dengue virus infection (Part B)</measure>
    <time_frame>Day 0 through Day 672</time_frame>
    <description>Occurrence of confirmed cases of Dengue virus infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events (Part A and B)</measure>
    <time_frame>Day 0 through 28 days post product administration</time_frame>
    <description>Occurrence of unsolicited non-serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed cases of Zika with symptoms (Part B only)</measure>
    <time_frame>Day 0 through Day 672</time_frame>
    <description>Occurrence of confirmed cases of Zika incidence with symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response to VRC-ZKADNA090-00-VP (Part A and B)</measure>
    <time_frame>Day 0 to 28 days post product administration</time_frame>
    <description>Antibody response as measured by ZIKV neutralization antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed cases of Zika (Part B only)</measure>
    <time_frame>Day 0 through Day 672</time_frame>
    <description>Occurrence of confirmed cases of Zika irrespective of symptoms</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Zika Virus</condition>
  <condition>Zika Virus Infection</condition>
  <condition>Virus Diseases</condition>
  <condition>Flavivirus Infections</condition>
  <condition>Flaviviral Diseases</condition>
  <condition>Flaviviridae Infections</condition>
  <condition>RNA Virus Infections</condition>
  <arm_group>
    <arm_group_label>Part A, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZIKV vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZIKV vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZIKV vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 8 mg of vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZIKV vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 1 mL of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-ZKADNA090-00-VP</intervention_name>
    <description>VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV</description>
    <arm_group_label>Part A, Group 1</arm_group_label>
    <arm_group_label>Part A, Group 2</arm_group_label>
    <arm_group_label>Part A, Group 3</arm_group_label>
    <arm_group_label>Part B, Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VRC-PBSPLA043-00-VP</intervention_name>
    <description>A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo</description>
    <arm_group_label>Part B, Group 5</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject must meet all of the following criteria:

        Part A:

          -  18 to 35 years of age

          -  Available for clinical follow-up through Study Week 32

        Part B:

          -  15 to 35 years of age

          -  Available for clinical follow-up through Study Week 96

        Part A and B:

          -  Able to provide proof of identity to the satisfaction of the clinician completing the
             enrollment process

          -  Able and willing to complete the informed consent process

          -  Able and willing to complete the Assessment of Understanding and to verbalize
             understanding of all questions answered incorrectly prior to signing consent/assent

          -  Willing to donate blood and urine to be stored and used for future research

          -  In good general health without clinically significant medical history

          -  Physical examination and laboratory results without clinically significant findings
             within the 56 days prior to randomization

          -  Weight &gt;30 kilograms (kg)

          -  Agree not to receive any licenses or investigational flavivirus vaccines through 4
             weeks after last product administration

          -  Accessible injection sites on each limb as follows: 1 injections site in the deltoid
             muscle of each arm and 1 injection site in the vastus lateralis muscle of each
             anterolateral thigh.

        Laboratory Criteria within 56 days prior to enrollment:

          -  Hemoglobin within site institutional normal limits

          -  Absolute neutrophil count (ANC) within site institutional normal limits

          -  Total lymphocyte count ≥800 cells/mm3

          -  Platelets = 125,000-510,000 cells/mm3

          -  Alanine aminotransferase (ALT) ≤1.5 x upper limit of normal (ULN) based on site
             institutional normal range for respective age group

          -  Serum creatinine ≤1.2 x ULN based on site institutional normal range for respective
             age group

          -  Negative result on an human immunodeficiency virus (HIV) test that meets local
             standards for identification of HIV infection

        Criteria applicable to women and adolescents of childbearing potential:

          -  Negative result on a human chorionic gonadotropin pregnancy test (urine or serum) on
             day of randomization before receiving study product

          -  Agree to use effective means of birth control from at least 21 days before
             randomization through 12 weeks after the last product administration

        Criteria applicable to adolescents:

          -  Capability of the parent/guardian of the minor to understand and comply with planned
             study procedures

          -  Capability of the minor and their parent/guardian to provide informed consent

        Exclusion Criteria:

        Criteria applicable to women and adolescents of childbearing potential:

          -  Breast-feeding or planning to become pregnant while participating through 12 weeks
             after the last product administration

        Participant has received any of the following:

          -  More than 10 days of systemic immunosuppressive medications or cytotoxic medications
             within the 4 weeks prior to randomization

          -  Any systemic immunosuppressive medications or cytotoxic medications within the 14 days
             prior to randomization

          -  Blood products within 16 weeks prior to randomization

          -  Immunoglobulin within 8 weeks prior to randomization

          -  Investigational research agents within 4 weeks prior to randomization or planning to
             receive investigational products while on the study

          -  Any vaccination within 2 weeks prior to randomization

          -  Any live attenuated vaccination within 4 weeks prior to randomization

          -  Current anti-tuberculosis (TB) prophylaxis or therapy

        Participant has any of the following:

          -  Confirmed history of ZIKV infection (as reported by participant)

          -  Serious reactions to vaccines

          -  Chronic angioedema or chronic urticarial

          -  Asthma that is not well-controlled

          -  Diabetes mellitus (type I or II)

          -  Clinically significant autoimmune disease or immunodeficiency

          -  Hypertension that is not well-controlled

          -  Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions)

          -  Significant bruising or bleeding difficulties with IM injections or blood draws

          -  Malignancy that is active or history of a malignancy that is likely to recur during
             the period of the study

          -  Seizure or treatment for a seizure disorder within the last 3 years

          -  Asplenia, functional asplenia or any condition resulting in the absence or removal of
             the spleen

          -  History of Guillain-Barre Syndrome

          -  Psychiatric condition that may preclude compliance with the protocol; past or present
             psychoses; or a history of suicide plan or attempt within 5 years prior to
             randomization

          -  Any medical psychiatric, or social condition that, in the judgment of the
             investigator, is a contraindication to protocol participation or impairs a
             participant's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Ledgerwood, DO</last_name>
    <role>Study Chair</role>
    <affiliation>VRC, NIAID, NIH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grace Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VRC, NIAID, NIH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phyllis Renehan</last_name>
    <phone>301-251-1161</phone>
    <email>vrc705@emmes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Linton</last_name>
    <phone>301-251-1161</phone>
    <email>vrc705@emmes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>QPS-Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Soto, CCRC</last_name>
      <phone>305-279-0015</phone>
      <phone_ext>4206</phone_ext>
      <email>maria.soto@qps.com</email>
    </contact>
    <contact_backup>
      <last_name>Lourdes Arnillas, CRC</last_name>
      <phone>305-279-0015</phone>
      <phone_ext>4221</phone_ext>
      <email>lourdes.arnillas@qps.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diane Krieger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital at Renaissance</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Rodriguez</last_name>
      <phone>956-362-2378</phone>
      <email>john.rodriguez@dhr-rgv.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria E Herrera, RN</last_name>
      <phone>956-362-2380</phone>
      <email>m.herrera@dhr-rgv.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas Da Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia de Araújo</last_name>
      <phone>55 31 3409-9255</phone>
      <email>gambarellicpc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gabriela Machado</last_name>
      <phone>55 31 3409-9255</phone>
      <email>gabriela.nucleo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Flavia Ribeiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Clínicas Do Instituto Central Do Hospital Das Clínicas Da FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania C Done</last_name>
      <phone>+55 11 2661-3344</phone>
      <email>agendamento.estudo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Leandro Concolato</last_name>
      <phone>+55 11 2661-2272</phone>
      <email>leandrocofarma@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Espér G Kallas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannina Rojas Melendez</last_name>
      <phone>+57 3183853250</phone>
      <email>yrojas@clinicadelacosta.co</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Ruiz Restrepo</last_name>
      <phone>+57 3005796743</phone>
      <email>kelly.yulieth.8903@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrés A Cadena Bonfanti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion y Diagnostico de Enfermedades Infecciosas</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Velandia</last_name>
      <phone>3167572596</phone>
      <email>quimicofarmaceutico@cdi.net.co</email>
    </contact>
    <contact_backup>
      <last_name>Carolina Rueda</last_name>
      <phone>3002556515</phone>
      <email>productoeninvestigacion@cdi.net.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luis Villar Centeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Civil Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Castillo Mondragon, MD</last_name>
      <phone>52 33 36145568</phone>
      <email>alcastillom@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Del Rayo Morfin Otero, MD</last_name>
      <phone>52 33 36145568</phone>
      <email>rayomorfin@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Del Rayo Morfin Otero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Conmemorativo Gorgas</name>
      <address>
        <city>Panamá</city>
        <state>San Miguelito Province</state>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherin Rosales, RN</last_name>
      <phone>507-527-4939</phone>
      <email>krosales@gorgas.gob.pa</email>
    </contact>
    <contact_backup>
      <last_name>Betsi Ortiz, RN</last_name>
      <phone>507-527-4939</phone>
      <email>bortiz@gorgas.gob.pa</email>
    </contact_backup>
    <investigator>
      <last_name>Néstor R Sosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asociacion Civil Selva Amazonica</name>
      <address>
        <city>Iquitos</city>
        <state>Maynas/Loreto</state>
        <zip>16001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma L Pezo, MPH</last_name>
      <phone>+51-965682004</phone>
      <email>lpezo@acsaperu.org</email>
    </contact>
    <contact_backup>
      <last_name>Wilfredo M Casapia, MD, MPH</last_name>
      <phone>+51-965621830</phone>
      <email>mcasapia@acsaperu.org</email>
    </contact_backup>
    <investigator>
      <last_name>Wilfredo M Casapia, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidad de Ensayos (UNIDEC) del Policlinico Universidad Nacional Mayor de San Marcos</name>
      <address>
        <city>Lima</city>
        <zip>15081</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny G Rosas Benancio, RN</last_name>
      <phone>511-4800401</phone>
      <email>fannysshhh@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sara R Milagros Tume Ruiz</last_name>
      <phone>511-4800401</phone>
      <email>stume@citbm.pe</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge L Sanchez Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation Inc./CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imaris Arroyo</last_name>
      <phone>787-840-2505</phone>
      <email>iarroyo@psm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth A Barranco-Santana</last_name>
      <phone>787-840-2505</phone>
      <email>crc@psm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth A Barranco-Santana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael O Mendoza-Rodriguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación de Investigación de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Juan Hospital Research Unit</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvia Pérez, MEd, MA, MPH</last_name>
      <phone>787-765-4186</phone>
      <email>eperez@sanjuanciudadpatria.com</email>
    </contact>
    <contact_backup>
      <last_name>Lizbeth M Fábregas, BS, MS</last_name>
      <phone>787-764-3083</phone>
      <email>lfabregas@sanjuanciudadpatria.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Rosario, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Midnela Acevedo-Flores, MT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Clinical and Translational Research Consortium</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemente Diaz, MD</last_name>
      <phone>787-759-0306</phone>
      <email>clemente.diaz@upr.edu</email>
    </contact>
    <investigator>
      <last_name>Clemente Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irma Febo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maribel Campos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W, Bundrant N, Koup RA, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 303 Study Team. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011 May 15;203(10):1396-404. doi: 10.1093/infdis/jir054. Epub 2011 Mar 11.</citation>
    <PMID>21398392</PMID>
  </reference>
  <reference>
    <citation>Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis. 2007 Dec 15;196(12):1732-40. doi: 10.1086/523650.</citation>
    <PMID>18190252</PMID>
  </reference>
  <reference>
    <citation>Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN, Gallagher JR, Chen X, Todd JP, Tsybovsky Y, Harris A, Huang YS, Higgs S, Vanlandingham DL, Andersen H, Lewis MG, De La Barrera R, Eckels KH, Jarman RG, Nason MC, Barouch DH, Roederer M, Kong WP, Mascola JR, Pierson TC, Graham BS. Rapid development of a DNA vaccine for Zika virus. Science. 2016 Oct 14;354(6309):237-240. Epub 2016 Sep 22.</citation>
    <PMID>27708058</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flavivirus</keyword>
  <keyword>Zika</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Virus-like Particles</keyword>
  <keyword>Zika vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Flaviviridae Infections</mesh_term>
    <mesh_term>Flavivirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

